ZA964838B - Treatment of Type II diabetes mellitus with amylin agonists. - Google Patents

Treatment of Type II diabetes mellitus with amylin agonists.

Info

Publication number
ZA964838B
ZA964838B ZA9604838A ZA964838A ZA964838B ZA 964838 B ZA964838 B ZA 964838B ZA 9604838 A ZA9604838 A ZA 9604838A ZA 964838 A ZA964838 A ZA 964838A ZA 964838 B ZA964838 B ZA 964838B
Authority
ZA
South Africa
Prior art keywords
diabetes mellitus
type
treatment
amylin agonists
amylin
Prior art date
Application number
ZA9604838A
Other languages
English (en)
Inventor
Orville G Kolterman
Robert G Thompson
John F Mullane
Original Assignee
Amylin Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amylin Pharmaceuticals Inc filed Critical Amylin Pharmaceuticals Inc
Publication of ZA964838B publication Critical patent/ZA964838B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA9604838A 1995-06-07 1996-06-07 Treatment of Type II diabetes mellitus with amylin agonists. ZA964838B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/483,188 US6143718A (en) 1995-06-07 1995-06-07 Treatment of Type II diabetes mellutis with amylin agonists

Publications (1)

Publication Number Publication Date
ZA964838B true ZA964838B (en) 1997-02-24

Family

ID=23919034

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9604838A ZA964838B (en) 1995-06-07 1996-06-07 Treatment of Type II diabetes mellitus with amylin agonists.

Country Status (19)

Country Link
US (2) US6143718A (enExample)
EP (1) EP0772451B1 (enExample)
JP (1) JP4009319B2 (enExample)
AT (1) ATE228849T1 (enExample)
AU (1) AU721489B2 (enExample)
BG (1) BG101230A (enExample)
CA (1) CA2196999C (enExample)
CZ (1) CZ289043B6 (enExample)
DE (1) DE69625157T2 (enExample)
DK (1) DK0772451T3 (enExample)
ES (1) ES2187659T3 (enExample)
HU (1) HUP9700368A3 (enExample)
IN (1) IN181672B (enExample)
NO (1) NO970519L (enExample)
PT (1) PT772451E (enExample)
RU (1) RU2166958C2 (enExample)
SK (1) SK18697A3 (enExample)
WO (1) WO1996040220A1 (enExample)
ZA (1) ZA964838B (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU222249B1 (hu) * 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
AU7685894A (en) * 1993-09-07 1995-03-27 Amylin Pharmaceuticals, Inc. Methods for regulating gastrointestinal motility
US6143718A (en) * 1995-06-07 2000-11-07 Amylin Pharmaceuticals, Inc. Treatment of Type II diabetes mellutis with amylin agonists
US7312196B2 (en) 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US6410511B2 (en) 1997-01-08 2002-06-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US7101853B2 (en) * 1997-05-06 2006-09-05 Amylin Pharmaceuticals, Inc. Method for treating or preventing gastritis using amylin or amylin agonists
US7910548B2 (en) * 1997-06-06 2011-03-22 Amylin Pharmaceuticals, Inc. Methods for treating obesity
JP4353544B2 (ja) * 1998-01-09 2009-10-28 アミリン・ファーマシューティカルズ，インコーポレイテッド アミリン作動薬ペプチド用製剤
US6087334A (en) * 1998-08-21 2000-07-11 Amylin Pharmaceuticals, Inc. Anti-diabetic peptides
NZ534557A (en) * 2002-01-08 2007-10-26 Amylin Pharmaceuticals Inc Use of amylin or amylin agonists in the manufacture of a medicament for use in the treatment of dyslipidemia, wherein the medicament reduces post-prandial triglyceride levels
WO2004004665A2 (en) * 2002-07-09 2004-01-15 Bristol-Myers Squibb Company Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
AU2004241242A1 (en) * 2003-05-14 2004-12-02 Emisphere Technologies, Inc. Compositions for delivering peptide YY and PYY agonists
EP1644027B1 (en) * 2003-07-16 2014-04-09 Evotec International GmbH Use of pleiotrophin for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome
EP2233497A3 (en) * 2004-02-11 2011-01-12 Amylin Pharmaceuticals, Inc. Amylin family peptides and methods for making and using them
JP2007523196A (ja) * 2004-02-20 2007-08-16 ライナット ニューロサイエンス コーポレイション Ｎｔ−４／５を用いて肥満または糖尿病を処置する方法
US7399744B2 (en) * 2004-03-04 2008-07-15 Amylin Pharmaceuticals, Inc. Methods for affecting body composition
EP1888043A4 (en) * 2005-03-11 2010-07-28 Endo Pharmaceuticals Solutions OCTREOTIDE FORMULATIONS WITH CONTROLLED RELEASE
US7759312B2 (en) * 2005-03-11 2010-07-20 Endo Pharmaceuticals Solutions Inc. Delivery of dry formulations of octreotide
US7935342B2 (en) * 2006-02-02 2011-05-03 Rinat Neuroscience Corp. Methods for treating obesity by administering a trkB antagonist
EP1988923A1 (en) * 2006-02-02 2008-11-12 Rinat Neuroscience Corp. Methods for treating unwanted weight loss or eating disorders by administering a trkb agonist
BRPI0720473A2 (pt) * 2006-12-20 2014-01-14 Rinat Neuroscience Corp Agonistas de trkb para tratamento de distúbios autoimunes
CA2705708A1 (en) * 2007-11-14 2009-05-22 Amylin Pharmaceuticals, Inc. Methods for treating obesity and obesity related diseases and disorders
US8071537B2 (en) * 2008-06-25 2011-12-06 Endo Pharmaceuticals Solutions Inc. Implantable device for the sustained release of a polypeptide
JP5536053B2 (ja) 2008-06-25 2014-07-02 エンド ファーマスーティカルズ ソリューションズ インコーポレイテッド． 離型剤を有するオクトレオチドインプラント
EP3228320B1 (de) 2008-10-17 2019-12-18 Sanofi-Aventis Deutschland GmbH Kombination von einem insulin und einem glp-1-agonisten
JP2009149684A (ja) * 2009-03-11 2009-07-09 Amylin Pharmaceut Inc アミリン作動薬ペプチド用製剤
EP2762150A1 (en) * 2009-03-12 2014-08-06 Nordic Bioscience A/S Treatment of Diabetes and Metabolic Syndrome
US20110118180A1 (en) * 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Method of treatment of diabetes type 2 comprising add-on therapy to metformin
US20110118178A1 (en) * 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin
PT2554183T (pt) 2009-11-13 2018-07-09 Sanofi Aventis Deutschland Composição farmacêutica que compreende um agonista de glp-1, uma insulina e metionina
PE20121316A1 (es) 2009-11-13 2012-10-05 Sanofi Aventis Deutschland Composicion farmaceutica que comprende un agonista de glp-1 y metionina
US20140148384A1 (en) 2010-08-30 2014-05-29 Sanofi-Aventis Deutschland Gmbh Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
CN108079281A (zh) 2011-08-29 2018-05-29 赛诺菲-安万特德国有限公司 用于2型糖尿病患者中的血糖控制的药物组合
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
BR102013017626A2 (pt) * 2013-06-14 2015-02-10 Univ Rio De Janeiro Bioconjugados não aglomerantes de amilinomiméticos com polietilenoglicol, uso de bioconjugados não aglomerantes de amilinomiméticos com polietilenoglicol, composições farmacêuticas de baixa toxicidade, adjuvante para a prevenção ou tratamento das doenças, medicamento, método de tratamento ou prevenção de doenças.
JP6728141B2 (ja) * 2014-09-04 2020-07-22 ノヴォ ノルディスク アー／エス 新規のアミリン及びカルシトニン受容体アゴニスト
TWI758239B (zh) 2014-12-12 2022-03-21 德商賽諾菲阿凡提斯德意志有限公司 甘精胰島素/利司那肽固定比率配製劑
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8720115D0 (en) * 1987-08-26 1987-09-30 Cooper G J S Treatment of diabetes mellitus
US5367052A (en) * 1987-04-27 1994-11-22 Amylin Pharmaceuticals, Inc. Amylin peptides
US5266561A (en) * 1988-01-11 1993-11-30 Amylin Pharmaceuticals, Inc. Treatment of type 2 diabetes mellitus
US5175145A (en) * 1988-08-26 1992-12-29 Amylin Pharmaceuticals, Inc. Treatment of diabetes mellitus with amylin agonists
US5264372A (en) * 1991-03-15 1993-11-23 Amylin Pharmaceuticals, Inc. Receptor-based screening methods for amylin agonists and antagonists
US5321008A (en) * 1991-01-10 1994-06-14 Amylin Pharmaceuticals, Inc. Methods and compositions for treatment of diabetes mellitus, hypoglycemia, and other conditions
US5234906A (en) * 1991-01-10 1993-08-10 Amylin Pharmaceuticals, Inc. Hyperglycemic compositions
HU222249B1 (hu) * 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
SK88793A3 (en) * 1991-11-19 1994-12-07 Amylin Pharmaceuticals Inc Amylin agonising peptides and their using
US5376638A (en) * 1992-09-01 1994-12-27 Amylin Pharmaceuticals, Inc. Methods for treating renin-related disorders with amylin antagonists
AU7685894A (en) * 1993-09-07 1995-03-27 Amylin Pharmaceuticals, Inc. Methods for regulating gastrointestinal motility
US6143718A (en) * 1995-06-07 2000-11-07 Amylin Pharmaceuticals, Inc. Treatment of Type II diabetes mellutis with amylin agonists
US6087334A (en) 1998-08-21 2000-07-11 Amylin Pharmaceuticals, Inc. Anti-diabetic peptides

Also Published As

Publication number Publication date
HU9700368D0 (en) 1997-04-28
WO1996040220A1 (en) 1996-12-19
DK0772451T3 (da) 2003-01-06
US6417164B1 (en) 2002-07-09
CZ289043B6 (cs) 2001-10-17
ATE228849T1 (de) 2002-12-15
BG101230A (en) 1997-10-31
AU721489B2 (en) 2000-07-06
HUP9700368A3 (en) 2001-03-28
JPH10503785A (ja) 1998-04-07
EP0772451A4 (en) 1998-09-30
HUP9700368A2 (hu) 1998-06-29
SK18697A3 (en) 1998-02-04
NO970519L (no) 1997-04-07
CA2196999C (en) 2012-09-04
US6143718A (en) 2000-11-07
PT772451E (pt) 2003-04-30
DE69625157T2 (de) 2003-04-17
RU2166958C2 (ru) 2001-05-20
ES2187659T3 (es) 2003-06-16
CZ33797A3 (en) 1997-07-16
JP4009319B2 (ja) 2007-11-14
CA2196999A1 (en) 1996-12-19
AU6268596A (en) 1996-12-30
NO970519D0 (no) 1997-02-05
IN181672B (enExample) 1998-08-29
DE69625157D1 (de) 2003-01-16
EP0772451A1 (en) 1997-05-14
EP0772451B1 (en) 2002-12-04

Similar Documents

Publication Publication Date Title
ZA964838B (en) Treatment of Type II diabetes mellitus with amylin agonists.
IL122718A0 (en) Methods for treating diabetes
EA199800316A1 (ru) СЕЛЕКТИВНЫЕ β-АДРЕНЕРГИЧЕСКИЕ АГОНИСТЫ
CA2071629A1 (en) Use of insulin sensitizing agents to treat hypertension
SI0804479T1 (sl) Metoda zdravljenja sladkorne bolezni z uporabo kgf
AU6337886A (en) Glutamine treatment of catabolic dysfunction
EP1952819A3 (en) Method for preventing gastritis using amylin or amylin agonists
IL107153A0 (en) Use of il-10 to prevent or treat insulin-dependent diabetes mellitus
BG104059A (en) Diabetes treatment with rosiglytazone and insulin
ZA975867B (en) Hypoglycemic and hypolipidemic compounds
ZA921107B (en) Method of treating Type I diabetes.
EP0630383A4 (en) METHODS FOR TREATING DIABETIS.
PL328959A1 (en) Method of treating or preventing interstitial cystitis
BG104058A (en) Diabetes treatment with thiazolydindion and sulphonylurea
IL126158A0 (en) Method for treating substance abuse
EP0719556A3 (en) Agent for the treatment of keratopathy
PL328949A1 (en) Method of treatng excessive aggression
DE3377650D1 (en) Hydantoin therapeutic agents
ES2141044A1 (es) Terapia con oxibutinina.
TW286300B (en) The process of etching organic high-molecule material
MX9700626A (es) USO DE AZASPIRANOS EN LA REPARACIaN DE COMPOSICIONES PARA TRATAR INFECCIONES OPORTUNISTAS.
HU896157D0 (en) Acupunctural needle, particularly for long-time acupunctural treatment
UA19610A (uk) Спосіб лікуваhhя опісторхозhої іhвазії
ES1005761U (es) Mecanismo para simulacion de juegos de embite sin uso de baraja